Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | MLYCD | O95822 | 13/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL608510 | 0.87 | CES1 (0.60) | CES1MLYCDTRPV1 | |
| SCHEMBL19056956 | 0.87 | CES1 (0.65) | CES1MLYCDTRPV1MAP2K4HDAC6 | |
| SCHEMBL28130460 | 0.85 | CES1 (0.58) | CES1MLYCDTRPV1 | |
| Zinc Chloride SCHEMBL28130545 | 0.80 | CES1 (0.52) | CES1MLYCDTRPV1 | |
| SCHEMBL5937390 | 0.79 | CES1 (0.61) | CES1MLYCDHDAC6HDAC1 | |
| SCHEMBL4502846 | 0.79 | CES1 (0.75) | CES1MLYCDHDAC6 | |
| SCHEMBL298629 | 0.74 | BCL2L1 (0.58) | — | |
| SCHEMBL22533041 | 0.73 | MLYCD (0.54) | CES1MLYCD | |
| SCHEMBL22733910 | 0.73 | HAO1 (0.50) | CES1MLYCDHDAC6 | |
| SCHEMBL6613440 | 0.73 | CES1 (0.53) | CES1MLYCDMAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266826-A1 | Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-30 | — | — | US | claimed |
| EP-1423386-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | claimed |
| WO-2003022842-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-20 | — | — | WO | claimed |
| US-20040266826-A1 | Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-30 | — | — | US | disclosed |
| EP-1423386-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003022842-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-20 | — | — | WO | disclosed |
| EP-0929508-B1 | LIQUID CRYSTALLINE (E,E)-BUTADIENE COMPOUNDS AND MIXTURES AND DEVICES CONTAINING SUCH COMPOUNDS | QINETIQ LTD (GB) | 2002-03-20 | — | — | EP | disclosed |
| US-6333082-B1 | USEFUL IN SUPER TWISTED NEMATIC LIQUID CRYSTAL DISPLAYS | QINETIQ LTD (GB) | 2001-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266826-A1 | Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors | TNF, MMP9, MMP1 | CES1 180/4885MLYCD 3366/4885TRPV1 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.